Avior Wealth Management LLC Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Avior Wealth Management LLC lifted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1,570.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,554 shares of the company’s stock after purchasing an additional 8,042 shares during the quarter. Avior Wealth Management LLC’s holdings in Prestige Consumer Healthcare were worth $668,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. grew its stake in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC boosted its stake in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank grew its position in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. International Assets Investment Management LLC increased its stake in Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Prestige Consumer Healthcare by 49.9% in the third quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock worth $84,000 after buying an additional 387 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

PBH has been the topic of a number of recent analyst reports. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday. Finally, DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $76.79 on Friday. The firm has a fifty day simple moving average of $80.08 and a two-hundred day simple moving average of $74.88. The firm has a market cap of $3.79 billion, a PE ratio of 18.68, a P/E/G ratio of 2.17 and a beta of 0.51. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 1-year low of $60.00 and a 1-year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same quarter in the previous year, the company posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue was down .9% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William P’pool sold 8,987 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last quarter. Company insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.